Speakers

Anne has over 25 years’ experience in pharma and biotech, before joining GSK, she served as the Chief Scientific Officer at BenevolentAI, working to maximise the value of AI/ML technologies to enhance and accelerate the end-to-end drug discovery process. Prior to that, Anne worked for Pfizer for over 15 years, where she was latterly Head of Pharmacology and COO for Pfizer Neusentis. During her tenure she led technology platform teams and drug discovery programs from early discovery through to clinical development across a wide range of therapeutic areas, including cardiovascular, pain, allergy & respiratory, genitourinary and neurodegeneration.  She has focused on pre-clinical portfolio management, technology investment and the generation of plate-based pharmacology and phenotypic data across a wide range of target classes and therapeutic modalities, all experiences which will bring incredible value, insights and leadership to the Target Discovery organization as we progress the new disease phenotype drug discovery approach.